MA43918A - Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 - Google Patents

Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Info

Publication number
MA43918A
MA43918A MA043918A MA43918A MA43918A MA 43918 A MA43918 A MA 43918A MA 043918 A MA043918 A MA 043918A MA 43918 A MA43918 A MA 43918A MA 43918 A MA43918 A MA 43918A
Authority
MA
Morocco
Prior art keywords
antagonist
prevention
treatment
pharmaceutical composition
active substance
Prior art date
Application number
MA043918A
Other languages
English (en)
Inventor
Yoshinobu Higuchi
Keiko Hirokawa
Yuki Iwayanagi
Akihisa Kaneko
Hidetomo Kitamura
Hiroaki Matsushita
Ryosuke Mihara
Tomohisa Saito
Yumi Yamamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA43918A publication Critical patent/MA43918A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
MA043918A 2015-04-14 2016-04-13 Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 MA43918A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015082699 2015-04-14
JP2016041641 2016-03-04

Publications (1)

Publication Number Publication Date
MA43918A true MA43918A (fr) 2018-12-05

Family

ID=57126544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043918A MA43918A (fr) 2015-04-14 2016-04-13 Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Country Status (25)

Country Link
US (3) US10544227B2 (fr)
EP (2) EP4650370A3 (fr)
JP (7) JP5954916B1 (fr)
KR (4) KR102886159B1 (fr)
CN (2) CN107614016B (fr)
AU (2) AU2016248786B2 (fr)
BR (1) BR112017022101A2 (fr)
CA (1) CA2980992C (fr)
DK (1) DK3284480T3 (fr)
ES (1) ES3036076T3 (fr)
FI (2) FI3284480T3 (fr)
FR (1) FR25C1042I1 (fr)
HR (1) HRP20250972T1 (fr)
HU (2) HUE072989T2 (fr)
LT (2) LT3284480T (fr)
MA (1) MA43918A (fr)
MX (2) MX390570B (fr)
NL (1) NL301347I2 (fr)
NO (1) NO2025047I1 (fr)
PL (1) PL3284480T3 (fr)
PT (1) PT3284480T (fr)
RU (1) RU2749512C2 (fr)
SI (1) SI3284480T1 (fr)
TW (4) TW202515609A (fr)
WO (1) WO2016167263A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017126488A1 (fr) * 2016-01-18 2017-07-27 持田製薬株式会社 Composition de traitement du psoriasis et procédé de traitement
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
PL3749353T3 (pl) * 2018-02-09 2025-12-08 Galderma Holding SA Nemolizumab w leczeniu atopowego zapalenia skóry z przeczosami o nasileniu od umiarkowanego do ciężkiego
CN112533675A (zh) * 2018-04-25 2021-03-19 基尼克萨制药有限公司 通过递送抗OSMRβ抗体治疗皮肤疾病或病症
JP7549530B2 (ja) 2018-05-21 2024-09-11 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP7671275B2 (ja) * 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
WO2021100794A1 (fr) * 2019-11-20 2021-05-27 中外製薬株式会社 Préparation pharmaceutique comprenant un anticorps
US12551528B2 (en) * 2020-01-24 2026-02-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
WO2022113316A1 (fr) * 2020-11-30 2022-06-02 マルホ株式会社 Inhibiteur de la progression de la fibrose
WO2022168962A1 (fr) * 2021-02-04 2022-08-11 国立大学法人九州大学 Agent pour supprimer la production d'il-31 et composition pharmaceutique la contenant
CN115181183B (zh) * 2022-06-23 2023-11-03 恺佧生物科技(上海)有限公司 一种il-31ra抗体以及其构建方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575014A5 (fr) 1973-05-25 1976-04-30 Alusuisse
JPS5328498Y2 (fr) 1973-08-17 1978-07-18
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
RU2151612C1 (ru) 1992-12-01 2000-06-27 Протеин Дизайн Лэбс, Инк. Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
BR9910568A (pt) 1998-04-30 2001-09-11 Tanox Inc Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
WO1999067290A1 (fr) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Nouvelles proteines receptrices d'hemopoïetine
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1221482B1 (fr) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Proteine receptrice d'hemopoietine (nr12)
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
EP1325115B1 (fr) 2000-06-26 2016-07-27 ZymoGenetics, Inc. Zcytor17, recepteur de la cytokine
EP1332209B1 (fr) 2000-09-08 2009-11-11 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
CA2418835A1 (fr) 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
PL366469A1 (en) 2001-04-05 2005-02-07 Immuno-Biological Laboratories Co, Ltd. Anti-osteopontin antibody and use thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2004003140A2 (fr) 2002-01-18 2004-01-08 Zymogenetics, Inc. Recepteurs multimeres des cytokines contenant zcytor17
RU2490276C2 (ru) 2002-01-18 2013-08-20 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
CN100412090C (zh) 2002-05-01 2008-08-20 舍林股份公司 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
KR101230724B1 (ko) 2003-03-04 2013-02-07 알렉시온 파마슈티칼스, 인코포레이티드 항원 제공 세포의 내성을 유도함으로써 자가 면역 질환 치료 방법
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
CA2555340A1 (fr) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Nouvelles disruptions geniques, compositions et procedes associes
EP1773391A4 (fr) 2004-06-25 2009-01-21 Medimmune Inc Augmentation de la production d'anticorps de recombinaison dans des cellules de mamiferes par mutagenese sur le site
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1671642A1 (fr) 2004-12-15 2006-06-21 Universite D'angers Composés contenant des (ant)agonistes de l'oncostatin M (OSM), IL-31 et IFN-gamma pour moduler la migration et fonction de keratinocytes au moyen d'un recepteur comprenant l'OSMRbeta comme sousunité, et applications correspondantes
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
ES2579758T3 (es) 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
EP1858924A1 (fr) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methodes de traitement d'affections de la peau en employant un antagoniste de il-31ra
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
RU2444528C2 (ru) 2005-05-06 2012-03-10 Займоджинетикс, Инк. Моноклональные антитела против il-31 и способы применения
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
EP2001906A2 (fr) 2006-01-10 2008-12-17 Zymogenetics, Inc. PROCÉDÉS DE TRAITEMENT DE LA DOULEUR ET DE L'INFLAMMATION DANS LE TISSU NEURONAL METTANT EN OEUVRE DES ANTAGONISTES IL-31Ra ET OSMRb
EP2463305B1 (fr) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Anticorps pour OX-2/CD200 et utilisations associées
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
ES2544888T3 (es) 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
US7858756B2 (en) 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
EP2061811A2 (fr) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Séquences de zones variables d'anticorps monoclonaux il-31, et procédés d'utilisation
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
CA2672215A1 (fr) 2006-12-11 2008-06-19 Wyeth Methodes et compositions pour le traitement et le controle d'un traitement de troubles associes a il-13
WO2008100995A1 (fr) 2007-02-14 2008-08-21 Vaccinex, Inc. Anticorps humains anti-cd100
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
WO2008114733A1 (fr) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-claudine-4
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
JP2010531340A (ja) 2007-07-10 2010-09-24 エフ．ホフマン−ラ ロシュ アーゲー 新規処方物
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
TWI548418B (zh) * 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
CA2708065C (fr) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique contre le prurit
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31
KR20160062207A (ko) 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
WO2014145159A2 (fr) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d'utilisation
US9198898B2 (en) * 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2018156367A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US10554227B2 (en) * 2017-03-10 2020-02-04 Western Digital Technologies, Inc. Decoding optimization for channel mismatch
US10493149B2 (en) 2017-04-11 2019-12-03 Kiniksa Pharmaceuticals, Ltd. Stable anti-OSMR antibody formulation
JP7549530B2 (ja) 2018-05-21 2024-09-11 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2021100794A1 (fr) 2019-11-20 2021-05-27 中外製薬株式会社 Préparation pharmaceutique comprenant un anticorps
CA3189847A1 (fr) 2020-09-01 2022-03-10 Naoki Fukazawa Composition pharmaceutique pour la prevention et/ou le traitement du prurit en dialyse contenant comme principe actif un antagoniste de l'il-31
WO2022113316A1 (fr) 2020-11-30 2022-06-02 マルホ株式会社 Inhibiteur de la progression de la fibrose
WO2023120561A1 (fr) 2021-12-22 2023-06-29 中外製薬株式会社 Variant d'anticorps à activité biologique réduite

Also Published As

Publication number Publication date
HUS2500042I1 (hu) 2025-11-28
FI3284480T3 (fi) 2025-09-11
AU2022201346B2 (en) 2024-11-21
HRP20250972T1 (hr) 2025-10-10
KR20240033097A (ko) 2024-03-12
US20200102396A1 (en) 2020-04-02
US20180079817A1 (en) 2018-03-22
AU2016248786B2 (en) 2022-01-20
EP3284480A1 (fr) 2018-02-21
EP4650370A3 (fr) 2026-03-11
AU2016248786A1 (en) 2017-10-26
JP2021105051A (ja) 2021-07-26
US20240018249A1 (en) 2024-01-18
RU2749512C2 (ru) 2021-06-11
KR102886159B1 (ko) 2025-11-13
NL301347I2 (nl) 2025-11-05
KR102641898B1 (ko) 2024-02-27
JP5954916B1 (ja) 2016-07-20
TW202327654A (zh) 2023-07-16
MX2021013139A (es) 2021-11-25
TWI826814B (zh) 2023-12-21
WO2016167263A1 (fr) 2016-10-20
CN107614016A (zh) 2018-01-19
PT3284480T (pt) 2025-07-29
JP2021193124A (ja) 2021-12-23
KR20230043246A (ko) 2023-03-30
TWI738648B (zh) 2021-09-11
EP4650370A2 (fr) 2025-11-19
KR20170134748A (ko) 2017-12-06
CN107614016B (zh) 2022-06-17
AU2022201346A1 (en) 2022-03-24
US10544227B2 (en) 2020-01-28
NO2025047I1 (no) 2025-10-23
FIC20250033I1 (fi) 2025-10-22
JPWO2016167263A1 (ja) 2017-06-01
JP6887212B2 (ja) 2021-06-16
EP3284480B1 (fr) 2025-07-02
JP2020075937A (ja) 2020-05-21
BR112017022101A2 (pt) 2018-07-31
PL3284480T3 (pl) 2025-11-12
ES3036076T3 (en) 2025-09-12
JP2017160178A (ja) 2017-09-14
FR25C1042I1 (fr) 2025-12-19
TW202515609A (zh) 2025-04-16
KR20210145295A (ko) 2021-12-01
KR102514173B1 (ko) 2023-03-27
JP6654967B2 (ja) 2020-02-26
RU2017138551A3 (fr) 2019-09-30
TW201642905A (zh) 2016-12-16
TW202146048A (zh) 2021-12-16
JP2025122131A (ja) 2025-08-20
MX2017013141A (es) 2018-02-21
JP2023134842A (ja) 2023-09-27
US11773173B2 (en) 2023-10-03
SI3284480T1 (sl) 2025-09-30
LT3284480T (lt) 2025-08-11
LTPA2025537I1 (fr) 2025-11-10
EP3284480A4 (fr) 2018-12-05
US12441804B2 (en) 2025-10-14
DK3284480T3 (da) 2025-09-08
RU2017138551A (ru) 2019-05-14
CA2980992C (fr) 2024-01-23
CN114848823A (zh) 2022-08-05
CA2980992A1 (fr) 2016-10-20
HUE072989T2 (hu) 2025-12-28
MX390570B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
FR25C1042I1 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EP2818482A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2824114A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2818481A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EP3375448A4 (fr) Souche ayant la capacité d'inhiber l'obésité et composition pharmaceutique la contenant
EP3351254A4 (fr) Composition pour la prévention ou le traitement de maladies inflammatoires, contenant, en tant que principe actif, des cellules souches suexprimant sod3
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP2825049A4 (fr) Formulation contenant un silicate de calcium particulaire et clonostachys rosea pour le traitement de plantes
EP3539951A4 (fr) Nouveau composé de pyrimidine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement du cancer et des maladies inflammatoires
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EP3403658C0 (fr) Composition pour le traitement des maladies neuro-inflammatoires contenant des cellules souches neurales ou leur sécrétome comme ingrédient actif
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EP2572721A4 (fr) Composition pharmaceutique comprenant un inhibiteur de hif-2 comme ingrédient actif pour la prévention ou le traitement de l'arthrite
EP3391904A4 (fr) Composition pharmaceutique contenant un anticorps anti-récepteur de la tslp humaine
EP3489252A4 (fr) Peptide ayant une activité anticancéreuse, composition pharmaceutique pour le traitement et la prévention du cancer, composition alimentaire de santé fonctionnelle et composition cosmétique fonctionnelle le contenant en tant que principe actif
EP3417853A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
EP3675874A4 (fr) Composition pharmaceutique pour le traitement des chéloïdes et ses utilisations
EP3517133A4 (fr) Composition pharmaceutique contenant un inhibiteur de mtor pour le traitement de la dégénérescence maculaire
HK1257296A1 (zh) 新的化合物及其用途
EP3336100A4 (fr) Peptide ayant pour effet de prévenir ou traiter des maladies du système nerveux central et composition pharmaceutique pour la prévention et le traitement de maladies du système nerveux central, contenant ce dernier en tant que principe actif
EP2857037A4 (fr) Agent de prévention et/ou de traitement d'une douleur neuropathique périphérique causée par un médicament anticancéreux